{"id":{"repo_id":"cork","oai_identifier":"oai:cora.ucc.ie:10468/18157"},"canonical_url":"https://search.dev.ndltd.org/etd/cork/oai:cora.ucc.ie:10468/18157","repository":{"repo_id":"cork","name":"University College Cork","base_url":"https://cora.ucc.ie/server/oai/request"},"display":{"title":"The safety and efficacy of novel dual function coronary stent in porcine model of myocardial infarction","abstract":"Objectives: We aimed in this study to evaluate the effectiveness of a dual function coronary stent in both inhibiting In Stent Restenosis (ISR) and salvaging the injured myocardium following acute myocardial infarction in pigs. Background: For more than a decade, drug eluting stents have written a successful chapter in coronary revascularisation following myocardial infarction. However, none so far has further exploited these stents beyond their primary function as a scaffolding structure to maintain the patency of the vessel. We aim in this study to use these stents as a delivery platform of cardioprotective drug (IGF-1) downstream the coronary artery to the injured myocardium while maintaining the patency of the vessel via anti-proliferative drug (AZ1193). Methods: The stent coating was designed to deliver IGF-1 from the outer (external) layer while delivering AZ1193 to the vessel wall. AZ1193 was sandwiched between a basal layer of Ti02 and an outer layer of AL203 using Atomic Layer Deposition (ALD) technique while IGF-1 was coated over AL203 layer. In vitro studies evaluated the release profile of IGF-1 and AZ1193 from the stent. Four groups of stents were used in 36 pigs following induced myocardial infarction: TAZA stent (Ti02-AZ1193-AL203), TAZA IGF-1 stent (TAZA stent coated with IGF-1), TA stent (Ti02-AL203) and TA IGF-1 (TA stent coated with IGF-1). ISR, Infarct size and LV ejection fraction (LVEF) were evaluated after 6 weeks of stent implantation. Results: Mortality was higher in IGF-1 stent groups (TAZA IGF-1 and TA IGF-1) comparable to other groups. Mortality rate was 14.2% (N7), 30% (NlO), 0% (N6), and 25% (NB) in TAZA, TAZA IGF-1, TA, and TA IGF-1 stent groups respectively (P=0.82). There was a significant restenosis in all groups (78.45 ± 10.01 %, 74.76 ± 14.64 %, 63.72 ± 14.41, and 70.10 ± 4.86 in TAZA, TAZA IGF-1, TA, and TA IGF-1 stent groups) (P<0.01). There was no significant difference in ISR among the groups (P=0.26). IA/AAR was 28.3 ± 2.3, 29.9 ±2.8, 27.1 ±1.4 and 28.0 ±1.8 in TAZA, TAZA IGF-1, TA, and TA IGF-1 groups respectively. There was no significant difference in infarct size among the groups (P=0.39). Baseline LVEF was 40.1% ± 3.9%, 40.5% ± 1.8%, 42.9% ± 4.8%, and 42.3% ± 3.4% for TAZA, TAZA IGF-1, TA and TA IGF-1 stent groups respectively (P=0.56). AT 6 weeks, LVEF was 27.5% ± 2.2%, 28.6% ± 6%, 25.9% ± 4%, and 24.9% ± 5.8% for TAZA, TAZA IGF-1, TA and TA IGF-1 stent groups respectively (P=0.62). There was a significant decline in EF secondary to LV remodelling at 6 weeks (P<0.05). Conclusions: This study demonstrated the feasibility to develop dual function coronary stent carrying anti-restenotic and cardioprotective drugs. Despite favourable in vitro results, the stent failed to reduce ISR and infarct size or to improve LVEF.","abstract_html":"Objectives: We aimed in this study to evaluate the effectiveness of a dual function coronary stent in both inhibiting In Stent Restenosis (ISR) and salvaging the injured myocardium following acute myocardial infarction in pigs. Background: For more than a decade, drug eluting stents have written a successful chapter in coronary revascularisation following myocardial infarction. However, none so far has further exploited these stents beyond their primary function as a scaffolding structure to maintain the patency of the vessel. We aim in this study to use these stents as a delivery platform of cardioprotective drug (IGF-1) downstream the coronary artery to the injured myocardium while maintaining the patency of the vessel via anti-proliferative drug (AZ1193). Methods: The stent coating was designed to deliver IGF-1 from the outer (external) layer while delivering AZ1193 to the vessel wall. AZ1193 was sandwiched between a basal layer of Ti02 and an outer layer of AL203 using Atomic Layer Deposition (ALD) technique while IGF-1 was coated over AL203 layer. In vitro studies evaluated the release profile of IGF-1 and AZ1193 from the stent. Four groups of stents were used in 36 pigs following induced myocardial infarction: TAZA stent (Ti02-AZ1193-AL203), TAZA IGF-1 stent (TAZA stent coated with IGF-1), TA stent (Ti02-AL203) and TA IGF-1 (TA stent coated with IGF-1). ISR, Infarct size and LV ejection fraction (LVEF) were evaluated after 6 weeks of stent implantation. Results: Mortality was higher in IGF-1 stent groups (TAZA IGF-1 and TA IGF-1) comparable to other groups. Mortality rate was 14.2% (N7), 30% (NlO), 0% (N6), and 25% (NB) in TAZA, TAZA IGF-1, TA, and TA IGF-1 stent groups respectively (P=0.82). There was a significant restenosis in all groups (78.45 ± 10.01 %, 74.76 ± 14.64 %, 63.72 ± 14.41, and 70.10 ± 4.86 in TAZA, TAZA IGF-1, TA, and TA IGF-1 stent groups) (P<0.01). There was no significant difference in ISR among the groups (P=0.26). IA/AAR was 28.3 ± 2.3, 29.9 ±2.8, 27.1 ±1.4 and 28.0 ±1.8 in TAZA, TAZA IGF-1, TA, and TA IGF-1 groups respectively. There was no significant difference in infarct size among the groups (P=0.39). Baseline LVEF was 40.1% ± 3.9%, 40.5% ± 1.8%, 42.9% ± 4.8%, and 42.3% ± 3.4% for TAZA, TAZA IGF-1, TA and TA IGF-1 stent groups respectively (P=0.56). AT 6 weeks, LVEF was 27.5% ± 2.2%, 28.6% ± 6%, 25.9% ± 4%, and 24.9% ± 5.8% for TAZA, TAZA IGF-1, TA and TA IGF-1 stent groups respectively (P=0.62). There was a significant decline in EF secondary to LV remodelling at 6 weeks (P<0.05). Conclusions: This study demonstrated the feasibility to develop dual function coronary stent carrying anti-restenotic and cardioprotective drugs. Despite favourable in vitro results, the stent failed to reduce ISR and infarct size or to improve LVEF.","abstract_has_math":false,"creators":["Khider, Wisam"],"institution":"University College Cork","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Caplice, Noel M."],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018","date_published":"2018","updated_at":"2026-07-24T01:46:55Z","subjects":["Dual function coronary stent","Myocardial infarction","Anti-restenotic and cardioprotective drugs"],"languages":["en"],"rights":["© 2018, Wisam Khider."],"rights_urls":["https://creativecommons.org/licenses/by-nc-nd/4.0/"],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/10468/18157","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Caplice, Noel M."]},{"key":"dc:creator","label":"Author","values":["Khider, Wisam"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-11-06T12:54:52Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2025-11-06T12:54:52Z"]},{"key":"dc:date.issued","label":"Date","values":["2018"]},{"key":"dc:publisher","label":"Institution","values":["University College Cork"]},{"key":"dc:type","label":"Dc Type","values":["Doctoral thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["Doctoral"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["MD - Doctor of Medicine"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Dual function coronary stent","Myocardial infarction","Anti-restenotic and cardioprotective drugs"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["© 2018, Wisam Khider."]},{"key":"dc:rights.uri","label":"Rights URI","values":["https://creativecommons.org/licenses/by-nc-nd/4.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/10468/18157"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Objectives: We aimed in this study to evaluate the effectiveness of a dual function coronary stent in both inhibiting In Stent Restenosis (ISR) and salvaging the injured myocardium following acute myocardial infarction in pigs. Background: For more than a decade, drug eluting stents have written a successful chapter in coronary revascularisation following myocardial infarction. However, none so far has further exploited these stents beyond their primary function as a scaffolding structure to maintain the patency of the vessel. We aim in this study to use these stents as a delivery platform of cardioprotective drug (IGF-1) downstream the coronary artery to the injured myocardium while maintaining the patency of the vessel via anti-proliferative drug (AZ1193). Methods: The stent coating was designed to deliver IGF-1 from the outer (external) layer while delivering AZ1193 to the vessel wall. AZ1193 was sandwiched between a basal layer of Ti02 and an outer layer of AL203 using Atomic Layer Deposition (ALD) technique while IGF-1 was coated over AL203 layer. In vitro studies evaluated the release profile of IGF-1 and AZ1193 from the stent. Four groups of stents were used in 36 pigs following induced myocardial infarction: TAZA stent (Ti02-AZ1193-AL203), TAZA IGF-1 stent (TAZA stent coated with IGF-1), TA stent (Ti02-AL203) and TA IGF-1 (TA stent coated with IGF-1). ISR, Infarct size and LV ejection fraction (LVEF) were evaluated after 6 weeks of stent implantation. Results: Mortality was higher in IGF-1 stent groups (TAZA IGF-1 and TA IGF-1) comparable to other groups. Mortality rate was 14.2% (N7), 30% (NlO), 0% (N6), and 25% (NB) in TAZA, TAZA IGF-1, TA, and TA IGF-1 stent groups respectively (P=0.82). There was a significant restenosis in all groups (78.45 ± 10.01 %, 74.76 ± 14.64 %, 63.72 ± 14.41, and 70.10 ± 4.86 in TAZA, TAZA IGF-1, TA, and TA IGF-1 stent groups) (P<0.01). There was no significant difference in ISR among the groups (P=0.26). IA/AAR was 28.3 ± 2.3, 29.9 ±2.8, 27.1 ±1.4 and 28.0 ±1.8 in TAZA, TAZA IGF-1, TA, and TA IGF-1 groups respectively. There was no significant difference in infarct size among the groups (P=0.39). Baseline LVEF was 40.1% ± 3.9%, 40.5% ± 1.8%, 42.9% ± 4.8%, and 42.3% ± 3.4% for TAZA, TAZA IGF-1, TA and TA IGF-1 stent groups respectively (P=0.56). AT 6 weeks, LVEF was 27.5% ± 2.2%, 28.6% ± 6%, 25.9% ± 4%, and 24.9% ± 5.8% for TAZA, TAZA IGF-1, TA and TA IGF-1 stent groups respectively (P=0.62). There was a significant decline in EF secondary to LV remodelling at 6 weeks (P<0.05). Conclusions: This study demonstrated the feasibility to develop dual function coronary stent carrying anti-restenotic and cardioprotective drugs. Despite favourable in vitro results, the stent failed to reduce ISR and infarct size or to improve LVEF."]},{"key":"dc:format.mimetype","label":"Dc Format Mimetype","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["The safety and efficacy of novel dual function coronary stent in porcine model of myocardial infarction"]}]}],"canonical_facts":{"dc:contributor.advisor":["Caplice, Noel M."],"dc:creator":["Khider, Wisam"],"dc:date.accessioned":["2025-11-06T12:54:52Z"],"dc:date.available":["2025-11-06T12:54:52Z"],"dc:date.issued":["2018"],"dc:description.abstract":["Objectives: We aimed in this study to evaluate the effectiveness of a dual function coronary stent in both inhibiting In Stent Restenosis (ISR) and salvaging the injured myocardium following acute myocardial infarction in pigs. Background: For more than a decade, drug eluting stents have written a successful chapter in coronary revascularisation following myocardial infarction. However, none so far has further exploited these stents beyond their primary function as a scaffolding structure to maintain the patency of the vessel. We aim in this study to use these stents as a delivery platform of cardioprotective drug (IGF-1) downstream the coronary artery to the injured myocardium while maintaining the patency of the vessel via anti-proliferative drug (AZ1193). Methods: The stent coating was designed to deliver IGF-1 from the outer (external) layer while delivering AZ1193 to the vessel wall. AZ1193 was sandwiched between a basal layer of Ti02 and an outer layer of AL203 using Atomic Layer Deposition (ALD) technique while IGF-1 was coated over AL203 layer. In vitro studies evaluated the release profile of IGF-1 and AZ1193 from the stent. Four groups of stents were used in 36 pigs following induced myocardial infarction: TAZA stent (Ti02-AZ1193-AL203), TAZA IGF-1 stent (TAZA stent coated with IGF-1), TA stent (Ti02-AL203) and TA IGF-1 (TA stent coated with IGF-1). ISR, Infarct size and LV ejection fraction (LVEF) were evaluated after 6 weeks of stent implantation. Results: Mortality was higher in IGF-1 stent groups (TAZA IGF-1 and TA IGF-1) comparable to other groups. Mortality rate was 14.2% (N7), 30% (NlO), 0% (N6), and 25% (NB) in TAZA, TAZA IGF-1, TA, and TA IGF-1 stent groups respectively (P=0.82). There was a significant restenosis in all groups (78.45 ± 10.01 %, 74.76 ± 14.64 %, 63.72 ± 14.41, and 70.10 ± 4.86 in TAZA, TAZA IGF-1, TA, and TA IGF-1 stent groups) (P<0.01). There was no significant difference in ISR among the groups (P=0.26). IA/AAR was 28.3 ± 2.3, 29.9 ±2.8, 27.1 ±1.4 and 28.0 ±1.8 in TAZA, TAZA IGF-1, TA, and TA IGF-1 groups respectively. There was no significant difference in infarct size among the groups (P=0.39). Baseline LVEF was 40.1% ± 3.9%, 40.5% ± 1.8%, 42.9% ± 4.8%, and 42.3% ± 3.4% for TAZA, TAZA IGF-1, TA and TA IGF-1 stent groups respectively (P=0.56). AT 6 weeks, LVEF was 27.5% ± 2.2%, 28.6% ± 6%, 25.9% ± 4%, and 24.9% ± 5.8% for TAZA, TAZA IGF-1, TA and TA IGF-1 stent groups respectively (P=0.62). There was a significant decline in EF secondary to LV remodelling at 6 weeks (P<0.05). Conclusions: This study demonstrated the feasibility to develop dual function coronary stent carrying anti-restenotic and cardioprotective drugs. Despite favourable in vitro results, the stent failed to reduce ISR and infarct size or to improve LVEF."],"dc:format.mimetype":["application/pdf"],"dc:identifier.uri":["https://hdl.handle.net/10468/18157"],"dc:language.iso":["en"],"dc:publisher":["University College Cork"],"dc:rights":["© 2018, Wisam Khider."],"dc:rights.uri":["https://creativecommons.org/licenses/by-nc-nd/4.0/"],"dc:subject":["Dual function coronary stent","Myocardial infarction","Anti-restenotic and cardioprotective drugs"],"dc:title":["The safety and efficacy of novel dual function coronary stent in porcine model of myocardial infarction"],"dc:type":["Doctoral thesis"],"dc:type.qualificationlevel":["Doctoral"],"dc:type.qualificationname":["MD - Doctor of Medicine"]},"updated_at":"2026-07-24T01:46:55Z"}